GlassScriptPhysician profile
Jonathan J Roberts
NPI 1881751667
$8,134.94
in general payments reported to CMS, 2019-2025
15 companies · $68.53 in 2025
The $68.53 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,044 · 2020: $109 · 2022: $112 · 2023: $13.30 · 2024: $6,788 · 2025: $68.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,261 · Travel and Lodging: $379 · Food and Beverage: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,261.00 |
| Travel and Lodging | $378.85 |
| Food and Beverage | $229.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $6,717.06 | 2024 | |
| W. L. Gore & Associates, INC. | $344.79 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $256.58 | 2019-2022 | |
| Novo Nordisk INC | $236.32 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.89 | 2019 | |
| Merck Sharp & Dohme LLC | $92.68 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.01 | 2019 | |
| Lilly USA, LLC | $59.53 | 2019-2025 | Mounjaro, Zepbound |
| Allergan, INC. | $40.04 | 2019 | |
| Novartis Pharmaceuticals Corporation | $28.20 | 2023-2024 | |
| Dexcom, INC. | $24.00 | 2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $19.85 | 2025 | Trelegy Ellipta |
| Zyla Life Sciences, INC. | $19.71 | 2019 | |
| Abbvie INC. | $17.46 | 2025 | |
| Exact Sciences Corporation | $16.82 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.